118 related articles for article (PubMed ID: 36436197)
1. Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2.
Shaw B; Shortt J; Low M; Rogers B; Kaplan Z; Fedele P; Gregory G; Vilcassim S; Gilbertson M; Grigoriadis G; Opat S
Intern Med J; 2022 Dec; 52(12):2172-2175. PubMed ID: 36436197
[TBL] [Abstract][Full Text] [Related]
2. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
[TBL] [Abstract][Full Text] [Related]
3. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
[TBL] [Abstract][Full Text] [Related]
4. Mortality and burden of post-COVID-19 syndrome have reduced with time across SARS-CoV-2 variants in haematology patients.
Willan J; Agarwal G; Bienz N
Br J Haematol; 2023 May; 201(4):640-644. PubMed ID: 36861893
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 in patients with hematologic malignancy.
Langerbeins P; Hallek M
Blood; 2022 Jul; 140(3):236-252. PubMed ID: 35544585
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).
Cesaro S; Ljungman P; Mikulska M; Hirsch HH; von Lilienfeld-Toal M; Cordonnier C; Meylan S; Mehra V; Styczynski J; Marchesi F; Besson C; Baldanti F; Masculano RC; Beutel G; Einsele H; Azoulay E; Maertens J; de la Camara R; ; Pagano L
Leukemia; 2022 Jun; 36(6):1467-1480. PubMed ID: 35488021
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
Pinato DJ; Aguilar-Company J; Ferrante D; Hanbury G; Bower M; Salazar R; Mirallas O; Sureda A; Plaja A; Cucurull M; Mesia R; Townsend S; Jackson A; Dalla Pria A; Newsom-Davis T; Handford J; Sita-Lumsden A; Apthorp E; Vincenzi B; Bertuzzi A; Brunet J; Lambertini M; Maluquer C; Pedrazzoli P; Biello F; Sinclair A; Bawany S; Khalique S; Rossi S; Rogers L; Murphy C; Belessiotis K; Carmona-García MC; Sharkey R; García-Illescas D; Rizzo G; Perachino M; Saoudi-Gonzalez N; Doonga K; Fox L; Roldán E; Gaidano G; Ruiz-Camps I; Bruna R; Patriarca A; Martinez-Vila C; Cantini L; Zambelli A; Giusti R; Mazzoni F; Caliman E; Santoro A; Grosso F; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Prat A; Tucci M; Libertini M; Grisanti S; Mukherjee U; Diamantis N; Fusco V; Generali D; Provenzano S; Gennari A; Tabernero J; Cortellini A;
Lancet Oncol; 2022 Jul; 23(7):865-875. PubMed ID: 35660139
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.
Wang L; Wang W; Xu R; Berger NA
Best Pract Res Clin Haematol; 2022 Sep; 35(3):101384. PubMed ID: 36494154
[TBL] [Abstract][Full Text] [Related]
10. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy.
Giesen N; Sprute R; Rüthrich M; Khodamoradi Y; Mellinghoff SC; Beutel G; Lueck C; Koldehoff M; Hentrich M; Sandherr M; von Bergwelt-Baildon M; Wolf HH; Hirsch HH; Wörmann B; Cornely OA; Köhler P; Schalk E; von Lilienfeld-Toal M;
Eur J Cancer; 2021 Apr; 147():154-160. PubMed ID: 33676266
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
McCaughan G; Di Ciaccio P; Ananda-Rajah M; Gilroy N; MacIntyre R; Teh B; Weinkove R; Curnow J; Szer J; Enjeti AK; Ross DM; Mulligan S; Trotman J; Dickinson M; Quach H; Choi P; Polizzotto MN; Tam CS; Ho PJ; Ku M; Gregory G; Gangatharan S; Hapgood G; Cochrane T; Cheah C; Gibbs S; Wei A; Johnston A; Greenwood M; Prince HM; Latimer M; Berkahn L; Wight J; Armytage T; Hamad N
Intern Med J; 2021 May; 51(5):763-768. PubMed ID: 34047035
[TBL] [Abstract][Full Text] [Related]
12. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies.
Chien KS; Peterson CB; Young E; Chihara D; Manasanch EE; Ramdial JL; Thompson PA
Blood Adv; 2023 Oct; 7(19):5691-5697. PubMed ID: 36696472
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
16. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
[TBL] [Abstract][Full Text] [Related]
17. Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study.
Lund LC; Rahbek MT; Brown P; Obel N; Hallas J; Frederiksen H
Eur J Haematol; 2023 Dec; 111(6):946-950. PubMed ID: 37740535
[TBL] [Abstract][Full Text] [Related]
18. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
[TBL] [Abstract][Full Text] [Related]
20. Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Cook LB; O'Dell G; Vourvou E; Palanicawandar R; Marks S; Milojkovic D; Apperley JF; Loaiza S; Claudiani S; Bua M; Hockings C; Macdonald D; Chaidos A; Pavlu J; Cooper N; Fidler S; Randell P; Innes AJ
Nat Commun; 2022 Nov; 13(1):6922. PubMed ID: 36376307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
